64 results
8-K
EX-99.1
EDIT
Editas Medicine, Inc.
14 Jun 24
All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion
6:04am
., Department of Pediatric Hematology Oncology and Blood and Marrow Transplantation, Cleveland Clinic Children’s, Cleveland, OH, United States
Date/Time
8-K
EX-99.2
EDIT
Editas Medicine, Inc.
14 Jun 24
All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion
6:04am
Author: Rabi Hanna, M.D., Department of Pediatric Hematology Oncology and Blood and Marrow Transplantation, Cleveland Clinic Children’s, Cleveland
S-3ASR
EX-1.2
EDIT
Editas Medicine, Inc.
28 Feb 24
Automatic shelf registration
5:13pm
that are:
(A) the subject of any sanctions administered or enforced by the U.S. Department of Treasury’s Office of Foreign Assets Control (“OFAC”) , the United … , registrar or depositary, (viii) filing fees and expenses, if any, of the Commission and the FINRA Corporate Financing Department (including, with respect
8-K
EX-99.1
2f0p2e
11 Dec 23
Regulation FD Disclosure
4:23pm
8-K
EX-1.1
j2rtejqp71aa
15 Jun 23
Editas Medicine Announces Offering of Common Stock
4:30pm
8-K
EX-99.1
vhc1fbccjm 4mq
9 Jun 23
Regulation FD Disclosure
6:01am
8-K
EX-1.1
t4x5hmub8 2qv8y
14 May 21
Entry into a Material Definitive Agreement
4:57pm
8-K
EX-99.1
cuco0t 02a
21 Jan 21
Editas Medicine Announces Pricing of Offering of Common Stock
4:47pm
8-K
EX-1.1
k8v7f1xioug7ppt2
21 Jan 21
Editas Medicine Announces Pricing of Offering of Common Stock
4:47pm
8-K
xh8hwgmd429llj 8jo
18 Dec 20
Departure of Directors or Certain Officers
4:22pm